Biocryst Pharmaceuticals reported $-73917000 in Pre-Tax Profit for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Alnylam Pharmaceuticals ALNY:US $ -239.36M 20.95M
Biocryst Pharmaceuticals BCRX:US $ -73.92M 58.39M
Chemocentryx CCXI:US $ -38.61M 1.92M
Chugai Pharma 4519:JP Y 186206M 47766M
Daiichi Sankyo 4568:JP Y -52370M 92301M
Enanta Pharmaceuticals ENTA:US $ -33.59M 3.44M
Intra Cellular Therapies ITCI:US $ -72.11M 13.62M
IONIS PHARMACEUT IONS:US $ -64M 289M
Karyopharm Therapeutics KPTI:US $ -41269000 79.87M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Neurocrine Biosciences NBIX:US $ 21.4M 35.2M
Novavax NVAX:US $ 206.07M 1035.74M
Ptc Therapeutics PTCT:US $ -121.89M 16.72M
Regeneron Pharmaceuticals REGN:US $ 1119.1M 1986M
Sarepta Therapeutics SRPT:US $ -104.15M 17.74M
Ultragenyx Pharmaceutical RARE:US $ -151.76M 29.32M
YTE INCY:US $ 172.84M 1.75M